Hims & Hers CEO Andrew Dudum defends company against Federal Trade Commission lawsuit over data sharing and subscription models.
Hims & Hers CEO Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit, arguing that the agency's legal action reflects a desire for publicity rather than a genuine resolution. During an interview with CNBC, Andrew Dudum stated that the lawsuit stems from a misunderstanding of how the company is disrupting traditional healthcare systems. In July, the Federal Trade Commission, Los Angeles County, and Utah filed the suit, accusing Hims & Hers of sharing user health data with advertisers like Meta and Snap, charging for prescriptions before patients speak with providers, and making it difficult to users to cancel subscriptions. Andrew Dudum countered that the company's business model is built on increasing patient access to care. He also addressed the company's transition from compounded GLP-1 drugs to branded versions, noting that the company applied pressure to the system to ensure affordable access for consumers. Furthermore, Andrew Dudum highlighted the company's future plans to become 'AI native' by leveraging closed-loop data sets to transform healthcare delivery.